Section 183: Epitranscriptomics and RNA Modifications in CBS/PSP

Introduction

Building upon our understanding of RNA metabolism dysregulation in neurodegenerative diseases, this section focuses on epitranscriptomics — the study of RNA modifications and their functional consequences — in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These 4R-tauopathies exhibit specific patterns of RNA modification dysregulation that represent novel therapeutic targets.

Epitranscriptomic modifications regulate nearly every aspect of RNA metabolism, including:

• mRNA stability and decay — determining how long transcripts persist in the cell

• Translation efficiency — controlling protein synthesis rates

• RNA localization — directing transcripts to specific cellular compartments

• Splicing decisions — influencing alternative splicing patterns

In tauopathies like CBS/PSP, these regulatory layers become disrupted, contributing to tau protein dysregulation, synaptic failure, and neuronal death. This section examines the key RNA modifications, their dysregulation in 4R-tauopathy, and therapeutic strategies to restore proper RNA metabolism.

The Epitranscriptomic Landscape in Tauopathy

N6-Methyladenosine (m6A): The Dominant RNA Modification

m6A is the most prevalent internal modification in eukaryotic mRNA, occurring on average at 1-3 sites per transcript. This modification is installed by a multiprotein “writer” complex and removed by “eraser” enzymes, with function executed by “reader” proteins that interpret the modification code^{1N6-methyladenosine modifications in Alzheimer's disease2020 · Nature Neuroscience · DOI 10.1038/s41593-020-00717-0Open reference}.

flowchart TD
    subgraph "m6A Writers"
        A["METTL3<br/>Catalytic subunit"] --> B["m6A Methyltransferase<br/>Complex"]
        C["METTL14<br/>Scaffold subunit"] --> B
        D["WTAP<br/>Regulatory subunit"] --> B
        E["VIRMA/KIAA1429<br/>3' UTR bias"] --> B
    end

    subgraph "m6A Erasers"
        F["FTO<br/>Demethylase"] <--> B
        G["ALKBH5<br/>Demethylase"] <--> B
    end

    subgraph "m6A Readers"
        B --> H["YTHDF1<br/>Translation initiation"]
        B --> I["YTHDF2<br/>mRNA decay"]
        B --> J["YTHDF3<br/>Co-translation"]
        B --> K["YTHDC1<br/>Splicing regulation"]
    end

    subgraph "Tauopathy Effects"
        H --> L["Synaptic protein<br/>translation"]
        I --> M["Tau mRNA<br/>stability"]
        J --> N["Aggregation-prone<br/>protein synthesis"]
        K --> O["Alternative splicing<br/>of tau isoforms"]
    end

    L --> P["Synaptic<br/>dysfunction"]
    M --> Q["Tau<br/>overexpression"]
    N --> R["Protein<br/>aggregation"]
    O --> S["4R tau<br/>imbalance"]

    P --> T["Neuronal<br/>death"]
    Q --> T
    R --> T
    S --> T

    style A fill:#0a1929,stroke:#1976d2
    style F fill:#2d0f0f,stroke:#d32f2f
    style H fill:#0a1f0a,stroke:#388e3c
    style T fill:#3b1114,stroke:#d32f2f

m5C: Methylcytosine in RNA

5-methylcytosine (m5C) is a modifications found in tRNA, rRNA, and mRNA that influences RNA stability and export^{2m5C RNA methylation regulates gene expression2019 · Cell · DOI 10.1016/j.cell.2019.10.006Open reference}:

Pseudouridine (Ψ): The Fifth Nucleotide

Pseudouridine, the most abundant RNA modification, stabilizes RNA structures and affects translation fidelity^{3Pseudouridine in mRNA and ncRNA2019 · Molecular Cell · DOI 10.1016/j.molcel.2019.10.016Open reference}:

Epitranscriptomic Dysregulation in CBS/PSP

m6A Alterations in Tauopathy

Research has identified specific patterns of m6A dysregulation in tauopathies:

Writer Complex Dysregulation

Reader Protein Alterations

The m6A reader proteins show distinct changes in tauopathy^{4m6A reader proteins in neurodegeneration2023 · Cellular and Molecular Neurobiology · DOI 10.1007/s10571-023-01326-8Open reference}:

• YTHDF1: Reduced in hippocampus and cortex, contributing to synaptic protein translation deficits

• YTHDF2: Elevated, promoting accelerated decay of protective transcripts

• YTHDF3: Dysregulated, affecting mRNA fate decisions

• YTHDC1: Altered splicing factor recruitment affects tau isoform expression

FTO and ALKBH5 (Erasers) in Tauopathy

The demethylases FTO and ALKBH5 provide dynamic control of m6A levels^{5FTO-mediated m6A demethylation in memory formation2022 · Nature Neuroscience · DOI 10.1038/s41593-021-00994-3Open reference6FTO polymorphisms and tauopathy progression2022 · Brain · DOI 10.1093/brain/awab367Open reference}:

FTO polymorphisms have been linked to:

• Altered risk for tauopathies

• Changes in 4R tau isoform ratios

• Modulation of age of onset

Impact on Tau Biology

Tau mRNA Stability and Translation

m6A modifications directly regulate tau protein expression^{7Dynamic m6A modification regulates tau pathology2021 · Nature Neuroscience · DOI 10.1038/s41593-021-00899-1Open reference}:

1. MAPT mRNA (tau transcript): Contains multiple m6A sites

2. YTHDF2 binding: Promotes tau mRNA decay — reduced YTHDF2 leads to tau overexpression

3. m6A site methylation: Alters ribosome loading and translation efficiency

Alternative Splicing of Tau Isoforms

In CBS/PSP, the 4R tau isoform predominates due to dysregulated splicing:

Synaptic Dysfunction Through m6A

Synaptic plasticity requires precise regulation of synaptic protein synthesis. m6A modifications are critical for this process^{8YTHDF1 regulates synaptic plasticity and memory2018 · Cell Reports · DOI 10.1016/j.celrep.2018.12.021Open reference}:

• YTHDF1 regulates translation of synaptic plasticity-related mRNAs

• Loss of YTHDF1 impairs long-term potentiation (LTP) and memory

• In tauopathy, YTHDF1 dysfunction contributes to synaptic failure

Neuroinflammation and m6A

m6A modifications regulate the inflammatory response:

Therapeutic Approaches

1. Modulating m6A Writers

METTL3 Modulation

Rationale for CBS/PSP: In tauopathy, global m6A elevation may increase stability of tau and other aggregation-prone transcripts. However, selective enhancement of specific m6A sites may restore synaptic protein synthesis.

METTL14-Targeted Approaches

METTL14 has shown protective effects in neurodegeneration^{9METTL14-mediated m6A modification in tauopathy2023 · Acta Neuropathologica · DOI 10.1007/s00401-023-02578-8Open reference}:

• METLL14 downregulation increases vulnerability to tau pathology

• Enhancing METTL14 may promote expression of neuroprotective genes

2. Targeting m6A Erasers

FTO Modulation

FTO is a promising therapeutic target^{6FTO polymorphisms and tauopathy progression2022 · Brain · DOI 10.1093/brain/awab367Open reference}:

FTO inhibitors may be beneficial by:

• Reducing tau mRNA stability

• Decreasing expression of aggregation-prone proteins

• Normalizing inflammatory transcript levels

ALKBH5 Modulation

ALKBH5 regulates nuclear mRNA m6A:

• ALKBH5 activators may restore proper splicing

• Particularly relevant for tau isoform regulation

3. Reader Protein Modulation

YTHDF1 Agonists

YTHDF1 enhances translation of synaptic proteins:

• Agonist approach: Promote synaptic protein synthesis

• Gene therapy: Increase YTHDF1 expression

• Small molecule modulators: Under development

YTHDF2 Modulation

YTHDF2 controls mRNA decay:

4. Combination Strategies

Epitranscriptomic therapies may synergize with other approaches:

5. Pseudouridine and m5C Targeting

These modifications offer alternative therapeutic angles:

• Pseudouridine synthases: Modulation may improve tRNA function

• m5C writers/readers: Target for restoring RNA stability

Biomarker Potential

Epitranscriptomic modifications in peripheral tissues may serve as biomarkers:

Clinical Trial Landscape

Integration with Treatment Rankings

Epitranscriptomic therapies represent an emerging approach in CBS/PSP treatment. Based on current evidence:

Research Directions

1. BBB-penetrant FTO inhibitors: Development of brain-permeable small molecules

2. Cell-type specific targeting: Distinguishing neuronal vs. glial epitranscriptomics

3. Personalized epitranscriptomics: Profiling individual RNA modification patterns

4. Combination approaches: Synergy with existing disease-modifying strategies

5. Biomarker development: Peripheral markers for target engagement

See Also

• m6A RNA Methylation in Neurodegeneration

• RNA Metabolism in AD

• Transcriptional Dysregulation in Tauopathy

• Section 182: Microbiome Metabolomics and SCFA Therapy

Summary

Epitranscriptomics represents a novel frontier in CBS/PSP therapeutics. The dynamic RNA modification landscape — particularly m6A and its associated machinery — is dysregulated in 4R-tauopathies, contributing to tau protein dysregulation, synaptic failure, and neuroinflammation. Therapeutic modulation of RNA modification pathways offers promising opportunities for disease modification, though significant challenges remain in developing brain-penetrant, cell-type-specific interventions. The integration of epitranscriptomic profiling with existing treatment strategies may enable personalized therapeutic approaches for CBS/PSP patients.